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In 2018, The University of Texas Health Science Center–Tyler and University of Texas
Rio Grande Valley were invited to develop clinical research units for an existing Clinical
and Translational Science Award (CTSA) consortium with the objective to equip medically
underserved, economically disadvantaged communities and subsequently to deploy COVID-19
clinical trials in response to a public health emergency.
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Established in 2011, the National Center for Advancing Translational Science (NCATS) is
one of 27 institutions constituting the U.S. National Institutes of Health (NIH). Its mandate
is to “understand—and thereby improve—translation, which is the process through which
new interventions that improve human health are developed and implemented.”1[p.5] To
this end, NCATS provides Clinical and Translational Science Awards (CTSAs) to foster
more multi-disciplinary collaborative research focused on addressing community needs and
building a translational science workforce. Dr. Elias Zerhouni initiated these awards in 2006
to replace legacy grants supporting general clinical research centers. As of 2019, there
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were approximately 60 CTSAs (Hubs) in the country,2 including the Center for Clinical
and Translational Sciences (CCTS) in Houston, Texas, which was established in 2006,
along with others, to integrate special populations into the full spectrum of clinical and
translational research, and to streamline such research through institutional review board
(IRB) reciprocity, data warehouses, biobanks, and other innovations. The CCTS catchment
area serves 13.5 million residents including 37.4% Hispanic in Houston, 91.7% Hispanic
in the Rio Grande Valley, and 15.2% Hispanic and 15.6% Black in Tyler, with an average
poverty rate of 21.2% across the three regions (Figure 1).
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In early 2018, we in Houston invited the University of Texas Health Science Center–Tyler
(UTHSC-Tyler) and The University of Texas Rio Grande Valley (UTRGV) to join the CCTS
as Clinical Research Units (CRUs). The term CRU is used expressly by NCATS and CTSAs
to denote a physical space dedicated to translational research that is collaborative, provides
a platform for workforce development, and operates clinical trials that translate research to
the community. The objective was to equip rural, medically underserved, and economically
disadvantaged communities such as Tyler in northeast Texas, El Paso in the west, and the
Rio Grande Valley in the south, to conduct collaborative research (Figure 1). Prior to the
pandemic, UTHSC-Tyler faculty members were also engaged in multiple community-based
initiatives aimed at improving population health by providing community health worker
training, especially in rural settings. The school also serves seven rural counties in the NIH
Rapid Acceleration of Diagnostics for Underserved Populations (RADx-Up) program in
order to improve access to COVID testing and identify COVID disease “hot spots.” Acting
as a COVID vaccine hub, UTHSC-Tyler has provided over 55,000 vaccinations to many
rural residents. The Nurse Family Partnership program provides home visiting nurses for
first time expectant mothers. Moreover, faculty members engage closely with local health
departments, serving as the local health authority for Smith County, Texas.
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These groups were poised to respond to the COVID-19 disaster, which began to unfold in
March 2020. The pandemic has acutely and disproportionately affected rural communities
that were already facing severe disadvantage in medical services and infrastructure,3 such
as those situated in east and southwestern Texas. As of April 7, 2021, the state of Texas
has reported more than 2,400,000 COVID-19 cases with more than 47,000 fatalities.4
COVID-19 has prompted a historic, rapid-fire launch of clinical trials of vaccines and
possible treatments, including administration of plasma from recovering COVID-19 patients.
Indeed, the NIH has expressly capitalized on existing CTSA hubs as launch pads for such
trials. This approach, repurposing existing resources to meet large-scale, unique, emergent
public health needs to combat COVID-19, has been successful in other cases. At UTHSC
Tyler, a new nurse coordinator was hired for the clinical research team to provide additional
support for the new COVID-19 clinical trials. To enable rapid responses for in-patient
recruitment and other trial needs, the entire research team was relocated to an entire floor
of a building proximate to the main campus hospital. An office and examination room
were dedicated to the CCTS CRU at that location. In April of 2021, a new COVID-19
clinic with three additional examination rooms was established in the pulmonary clinic area
on the UTHSC-Tyler North campus. The UTHSC-Houston site re deployed two full-time
physicians and two study coordinators and hired five new study coordinators, a laboratory
technician, and two research nurses. They repurposed space unoccupied by staff working at
J Health Care Poor Underserved. Author manuscript; available in PMC 2022 June 09.
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home for the new team. The same approach was used to rapidly train health care providers
in telehealth using the National Geriatric Network5 and to surveil COVID-19 in rural South
Africa.6
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The University of Texas Health Science Center–Tyler has now deployed CCTS support
to maximum effect, launching clinical trials of convalescent plasma (CONTAIN)7 against
COVID-19 as cases surged in surrounding East Texas communities. The University of Texas
Health Science Center–Tyler has since become one of the largest enrollment centers into this
nationwide trial, and nearly reached its yearly trial enrollment goal of 100 participants in six
months, with launch at Tyler in late August 2020 and 96 participants (28% Black) enrolled
by February 2021 (Table 1). The UTHSC-Houston site, launched at the same time, enrolled
146 participants. The trial ceased enrollment in March 2021, with 246 participants enrolled
across the three sites with 15% Black, 56% Hispanic, and 29% White (non-Hispanic) (Table
1).
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This trial was initiated in the U.S. in April 2020 to assess, in the absence of other proven
interventions at that time, whether in-patients with moderate to severe disease benefit
from convalescent plasma. Data have since shown that convalescent plasma may be less
effective than originally hoped, except to prevent severe disease in older adults with mild
symptoms.8,9 The University of Texas Health Science Center–Tyler will also open four
other COVID-19 projects following the same CCTS framework (Box 1). The University
of Texas Health Science Center–Tyler’s success demonstrates that given the right mandate,
funding, and infrastructure including strong CTSA-level support, small, rural underserved
communities can respond to public health emergencies. A similar approach was also
used by communities in Arkansas to ensure sustainable collection and equitable delivery
of COVID-19 convalescent plasma,10 but we had the additional challenge of reaching
populations across the majority of the vast geographical state of Texas encompassing
268,596 square miles.11 The UTHSC-Tyler’s success also highlights the benefits derived
by medically underserved communities from CTSAs and similar initiatives (e.g., the
proposed community health observing system for the Gulf of Mexico region).12 Finally,
UTHSC-Tyler’s experience demonstrates that important clinical trials can flourish even in
adversity, and even in communities that are not historically accustomed to or are distrustful
of medical research due to unethical historical and social circumstances, beginning with the
use of slaves and free Black people in medical experiments and including the U.S. Public
Health Service Study of Untreated Syphilis in the Negro Male at Tuskegee (often called the
Tuskegee Syphilis Study).13
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Trade-offs occurred due to the singular focus on COVID-19 clinical research, which
included decisions to table other non-COVID-19 research; reallocation of these resources
meant shifting away temporarily from other previously highly prioritized research including
non-medical opioid use research. Our CTSA also had a summit planned for diabetes and
obesity research development, which was tabled to give full attention to the exigency of the
NIH COVID-19 trials to which we had committed.
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The Houston CCTS in Brief
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The CCTS, having been one of the first CTSAs to be awarded, has become a center
for clinical and translational research for east and south Texas and nationally. It was
initially established as a partnership between The University of Texas Health Science
Center–Houston and The University of Texas MD Anderson Cancer Center, but it has
since grown to a consortium that now includes Rice University in Houston, UTHSC-Tyler,
and UTRGV. With a view to helping improve individual and public health in the region
and in the nation, the CCTS has endeavored since its inception to expand the translational
science workforce, lower research barriers, and streamline research through IRB reciprocity.
It also supports biobanks and data warehouses; integrates pediatric, elderly, Hispanic, and
LGBTQ+ populations into clinical and translational research; encourages collaboration
across disciplines; and supports neighboring institutions that lack CTSAs. The catchment
area now encompasses about 23,000 square miles with a population of 13,500,000 (4%
of the U.S. population) and some of the greatest diversity in the country. Houston is the
4th largest and most ethnically diverse city in the U.S. and is 45% Hispanic, 23% African
American, 7% Asian, 11% elderly, and 20% economically challenged; while northeast
Texas is about 16% African American, 15% Hispanic, 18% elderly, and 16% economically
challenged; and the Rio Grande Valley in South Texas is about 16% elderly and 30%
economically challenged.14 South Texas is 97% Hispanic and is home to 15.5% (4.5
million) of the state’s population of 29 million. South Texas residents struggle with lower
educational levels, less income, and less access to health care than the rest of the state. This
places them in greater danger of facing dire health problems such as obesity or cancer. To
date, the CCTS has provided services to 1,771 investigators and 3,970 projects, generating
more than 3,150 publications in journals with an average impact factor of 6.2. The health
challenges of the populations served by the CCTS at UTHSC-Tyler, UTRGV, and UT
Houston are shown in Figure 1.

Community Outreach for COVID-19-related Clinical Research in Northeast
Texas via UTHSC-Tyler and in Southwest Texas via UTRGV
The CCTS recruited UTHSC-Tyler in order to expand its reach into rural, medically
underserved east Texas communities. The Tyler and surrounding rural population is
characterized by high use of tobacco, incidence of lung cancer, alcoholism, suicide,
and other health issues associated with rural communities.15 The goal was to build and
fund a CRU that would bring together UTHSC-Tyler and community doctors to serve
approximately 1.3 million Texans and that could respond to the current pandemic (Figure 1).
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Although the push to recruit UTHSC-Tyler was initially predicated on the goal to extend
the diversity and geographic reach of the CCTS, the presence there of an interested and
accomplished pulmonary research team provided further impetus. The University of Texas
Health Science Center–Tyler has built an internationally recognized program on lung injury
and repair and pulmonary infectious diseases, the signature areas of its institutional research
enterprise. Faculty in the pulmonary division have considerable expertise in the conduct
of clinical trials in various lung diseases, although all other departments are relatively
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less experienced. The University also operates an experienced clinical research office that
provides study management, financial oversight, and compliance support, as well as a
strong Office of Sponsored Programs that provides both pre-award services including budget
review and subcontracting, and post-awards management of grant finances. The University
of Texas Health Science Center–Tyler will open become Texas’s newest medical school
in 2022 and will integrate with The University of Texas at Tyler academic campus. The
integration will expand collaborative opportunities to the nursing and pharmacology schools,
as well as others that will soon become part of the school of medicine. Additional personnel
will be available through this affiliation to participate in future CCTS research projects,
including supplements supporting clinical research projects related to COVID-19.
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Similarly, UTRGV was recruited to extend outreach to the primarily Hispanic communities
at the border with Mexico. The University of Texas Rio Grande Valley serves ~1.4 M
Texans, of whom >28% live in poverty (Figure 1) and is the site of the newest medical
school in Texas. The University of Texas Rio Grande Valley has now been integrated
into the CRU in Brownsville to enable multisite clinical research. It is now supported by
Clinical Trials Express, an infrastructure designed to streamline and centralize multisite
clinical trials, to lower research barriers, and to limit administrative redundancies; it is now
a contributor to and a user of the Clinical Data Warehouse, which today houses clinical
data on 4.1 million individuals. The CCTS has also launched several initiatives at UTRGV,
including workforce development to enhance diversity and good clinical practice.

Advent of New COVID-19 Projects in Rural Texas
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The CCTS vision to prepare Tyler and sociodemographically similar areas in Texas for
future emergent events has proved prescient, and the timeline from invitation to COVID-19
research is shown in Figure 2. As COVID-19 cases surged in the state in late June–July,
NCATS approached the CCTS with new clinical research opportunities (Box 1), initially to
help to complete the national placebo-controlled trial to determine the value of convalescent
plasma in patients hospitalized within seven days of the onset of COVID-19 symptoms. The
University of Texas Health Science Center–Tyler has recruited 96 patients to date. We note
that although early treatment with antibodies or late treatment with steroids or remdesivir
+/− anti-rheumatoid arthritis drug have now been shown to be beneficial,16,17,18,19 the value
of convalescent plasma remains unclear, highlighting the ongoing significance of this trial
in hospitalized patients. Additional projects include a COVID-19 database supported by
the National COVID Cohort Collaborative (N3C) and the All of Us Research program,
ACTIV-4 trials for testing anticoagulant strategies for outpatients and discharged patients at
risk of thrombotic complications from COVID-19, and a project supported by the RADxUP
program to survey and address testing disparities in vulnerable populations. The ACTIV-4
projects are national multicenter anticoagulant trials that either have been recently initiated
or will soon be. These projects represent new collaborations among CCTS components,
with the CCTS serving as a hub collaborating with other institutions across the country.
Following the same CCTS framework, the COVID-19 database and surveillance projects
have now been initiated at UTRGV in south Texas, extending the same trials being
conducted at UT Houston.
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Pressure to Launch
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The University of Texas Health Science Center–Tyler, UTRGV, and UT Houston were under
pressure to launch COVID-19 projects as cases surged in surrounding communities and in
the United States in March–June 2020. Accordingly, the convalescent plasma trial received
IRB approval at UTHSC-Tyler by reciprocity with UT Houston. This NCATS-designated
high-priority clinical research initiative was implemented in August 2020, about a month
after a mandate came from NCATS. Implementation involved using online communications
to enable rapid collaboration among clinical and basic science faculty at UTHSC-Tyler,
CCTS, and national principal investigators with input from NIH. Discovery and problemsolving sessions were and continue to be held to operationalize these large collaborative
projects and manage logistics, to best use existing resources. Challenges that were addressed
included training of less-experienced faculty on budget preparation, justification, time and
effort commitment, and alignment with other clinical responsibilities. For example, family
practice doctors at UTHSC-Tyler have little clinical research experience. They were asked to
determine among themselves how to best integrate project needs with their busy practices.
Notably, they developed a new paradigm that was unique among collaborating institutions,
in which an institutional roster of COVID-positive individuals was used to identify potential
trial participants. With IRB approval, this roster was used with telemedicine to enable
physician oversight of recruitment and validation of informed consent.
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In addition, all new investigators and staff recruited to support these projects were trained
in responsible conduct of research, with compliance followed through the Office of Clinical
Research. Similarly, subcontracting was accelerated, as were reviews of feasibility, project
milestones, and accountability. The UTHSC-Tyler IRB was also reorganized to improve
efficiency without compromising review, while the process to reconcile time and effort
was streamlined. Collectively, these efforts enabled rapid implementation of COVID-19
initiatives, enhanced research capacity, and fostered new collaborations across Texas and the
U.S.
The University of Texas Rio Grande Valley used the same CCTS framework and underwent
similar realignments to launch the same COVID-19 research projects (Figure 2). It is
important to note that this was the very first clinical research unit launched at UTRGV and
they have since enrolled four patients into the convalescent plasma trial since January 2021,
creating a new foundation for future research for the community. In particular, experienced
staff developed and wrote the RADxUP surveillance project in collaboration with public
health investigators at UTHSC-Tyler to quickly secure funding. The University of Texas Rio
Grande Valley will lead RADxUP with UTHSC-Tyler as a subsite.
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Conclusions
The University of Texas Health Science Center–Tyler’s and UTRGV’s nimble and
collaborative responses to COVID-19 mandates demonstrates that organizations in
underserved and disadvantaged areas are fully capable of participating in urgent clinical
trials, especially those that are of high national priority. The implementation of these trials
was expedited with backing and mentorship as well as resources and logistical support made
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available through the CCTS. Initiatives to lower research barriers (e.g., IRB reciprocity)
were also essential to accelerate implementation. Importantly, this experience has attracted
the support of the NIH/NCATS for future research initiatives not only at UTHSC-Tyler but
also at El Paso and Rio Grande Valley. Current and future collaborative federal projects may
provide these communities with early access to testing of potential medical breakthroughs
for COVID-19 and for future biomedical challenges.
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Box 1.
COVID-19 PROJECTS AT UTHSC-TYLER AND UTRGV AS OF MAY 5, 2021
Grant No.

Title

Status at
UTHSC-Tyler

Status at UTRGV

Author Manuscript

3UL1TR003167–
02S2

Convalescent Plasma
to Limit CoronavirusAssociated Complications
(CONTAIN)

Accrued 96
participants

Accrued 4
participants

3UL1TR003167–
02S3

N3C Data Enclave

Contributing data

N/A (data from
catchment area
collected by UT
Brownsville)

3UL1TR003167–
02S1_ap

Understanding and
Addressing COVID-19
Testing Disparities in
Vulnerable Populations: A
Multilevel and Multi-method
Approach

Initiated

Initiated

ACTIV-4 Outpatient

Anticoagulant versus aspirin
or placebo for COVID-19
patients predisposed to
vascular complications

Initiated

Initiated

ACTIV-4
Convalescent

Anticoagulant versus aspirin
or placebo for COVID-19
patients predisposed to
vascular complications

Initiated—
Enrollment to
begin May 2021

Initiated—
Enrollment to
begin May 2021
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Catchment areas and communities served by UTHSC-Tyler, UTRGV, and UTHSC-Houston.
Note:
Data sources: aUS Census Bureau (https://www.census.gov/)
bCenters for Disease Control and Prevention (https://nccd.cdc.gov/dhdspatlas/reports.aspx)
cCounty Health Rankings & Roadmaps (https://www.countyhealthrankings.org/)
dAmerican Lung Association (https://www.lung.org/)
eTexas Department of State Health Services (https://dshs.texas.gov/)
The CCTS Hub catchment area population is 13.5M
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Figure 2.

Timeline: From invitation to join CCTS to current enrollment in COVID-19 research.
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